皮質類固醇市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、給藥途徑、應用、地區和競爭格局分類，2021-2031年

全球皮質類固醇市場預計將從 2025 年的 62.4 億美元成長到 2031 年的 84.5 億美元，複合年成長率為 5.18%。

這些藥物，包括類固醇激素和模擬腎上腺皮質荷爾蒙功能的合成類似物，因其強大的抗發炎和免疫抑製作用而在醫學領域得到廣泛應用。推動這一成長的主要因素包括全球慢性呼吸系統疾病（如氣喘和慢性阻塞性肺病(COPD)）負擔的加重，以及需要長期治療管理的自體免疫疾病盛行率的上升。 2024 年，全球氣喘舉措(GINA) 報告稱，全球有超過 2.6 億人患有氣喘，凸顯了有效控制症狀的持續必要性。同時，全球人口老化也因與老齡化相關的發炎性疾病而進一步穩定了市場需求。

儘管市場對這些療法的需求強勁，但長期使用帶來的固有安全風險仍構成重大挑戰。長期使用皮質類固醇可能導致嚴重的副作用，例如骨質疏鬆、高血壓和荷爾蒙失衡，這往往會導致患者停止用藥或醫療機構轉而採用生物製藥等替代療法。這些安全隱患是市場擴張的主要障礙，因為監管機構和醫療專業人員對長期使用皮質類固醇療法持謹慎態度。

市場促進因素

慢性發炎和自體免疫疾病的日益普及是全球皮質類固醇市場的重要促進因素。隨著慢性阻塞性肺病（COPD）和類風濕性關節炎等疾病的日益普遍，對有效抗炎和免疫抑制療法的需求不斷成長，並且正在形成一個依賴這些藥物進行症狀控制和急性治療的穩定患者群體。根據世界衛生組織（WHO）截至2024年11月的情況說明書，2021年有350萬人死於COPD，凸顯了需要類固醇治療的呼吸系統疾病的巨大規模。此外，美國肺臟協會（ALA）2024年3月發布的《COPD趨勢總結》報告顯示，光是美國就有1,170萬成年人受到影響，強調了這些藥物在控制這些常見慢性疾病方面發揮的關鍵作用。

創新製劑的研發和聯合治療的進步進一步推動了市場擴張。製藥公司正大力投資先進的藥物傳遞系統，例如將皮質類固醇、長效BETA2受體激動劑和毒蕈鹼受體拮抗劑組合在一起的固定劑量複方吸入劑，以提高患者的依從性和臨床療效。這些技術進步正在解決與複雜給藥方案相關的依從性問題，並提高類固醇療法的商業性可行性。例如，根據葛蘭素史克（GSK）於2024年2月發布的《2023年度報告》，含有Fluticasone氟替卡鬆的三聯療法單吸入劑Trelegy Ellipta的全球銷售額成長了27%，達到22億英鎊。這表明，與傳統的單藥療法相比，具有更便利性和更高療效的創新給藥機制正在推動市場成長。

市場挑戰

長期使用糖皮質激素存在嚴重的安全隱患，這是限制全球糖皮質激素市場成長的主要障礙。儘管這些藥物臨床療效顯著，但長期使用與代謝和骨骼疾病等嚴重不利事件密切相關。這種風險狀況為醫療服務提供者在製定長期治療方案時帶來了相當大的限制，導致糖皮質激素的整體使用量下降。這些副作用問題限制了市場潛力，臨床醫生越來越傾向於選擇非類固醇類替代藥物進行長期治療。

近期臨床研究結果進一步強化了這個障礙，凸顯了關鍵患者族群面臨的巨大風險。歐洲呼吸學會引用的一項2024年研究顯示，長期接受糖皮質激素治療的氣喘患者，第2型糖尿病的累積發生率約為6.2%，骨質疏鬆症的累積發生率約為2.6%。這些數據使醫學界深刻意識到必須盡可能減少糖皮質激素的使用，並隨著生物製藥和其他安全性更高的替代療法的策略轉型，直接影響市場收入。

市場趨勢

緩釋注射劑的進步正在重塑市場格局，尤其是在骨關節炎疼痛管理領域，持續局部給藥至關重要。利用專有的微球技術，研發人員正在開發皮質類固醇製劑，這些製劑能夠提供持久鎮痛效果，同時最大限度地減少速效注射劑常見的全身血藥濃度激增。這項創新滿足了關節保守治療中持續緩解症狀的迫切需求，並減少了慢性疾病所需的關節內給藥頻率。例如，Pacilla Biosciences在2025年2月報告稱，其緩釋曲安奈德注射劑Zirretta在2024年的商業性銷售額達到了1.181億美元，這體現了這些長效製劑的商業化應用。

同時，為了克服眼藥水帶來的依從性負擔，尤其是在眼科領域，向局部和非全身給藥途徑的策略性轉變正在進行中。各公司正在推出生物可吸收的淚小管植入物和植入，以實現類固醇直接、穩定地輸送到目標組織，從而確保治療的連續性並降低眼表毒性。這種方法使患者能夠有效地將治療效果與眼科手術後自我管理複雜給藥方案的能力分開。為了支持向醫師給藥系統的轉變，Ocular Therapeutics公司於2025年3月宣布，其2024年的淨銷售額達到6,370萬美元，主要得益於其地塞米松眼藥植入Dextenza的銷售。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球皮質類固醇市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（糖皮質激素、鹽皮質激素）
  • 給藥途徑（吸入、外用、注射、口服）
  • 依應用領域（皮膚過敏、消化系統疾病、內分泌系統疾病、急性呼吸系統疾病、風濕性疾病等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美皮質類固醇市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲皮質類固醇市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區皮質類固醇市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲皮質類固醇市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美皮質類固醇市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球皮質類固醇市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie Inc.
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Corticosteroids Market is projected to expand from USD 6.24 billion in 2025 to USD 8.45 billion by 2031, achieving a CAGR of 5.18%. These pharmacological agents, comprising steroid hormones and synthetic analogues that replicate the functions of adrenal cortex hormones, are extensively employed in medicine for their potent anti-inflammatory and immunosuppressive properties. The primary factor fueling this growth is the increasing global burden of chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, along with a rising prevalence of autoimmune disorders that necessitate long-term therapeutic management. In 2024, the Global Initiative for Asthma reported that asthma impacts over 260 million individuals worldwide, underscoring the enduring need for effective symptom control, while the aging global population further stabilizes market demand due to age-related inflammatory conditions.

Despite the strong demand for these therapeutics, the market faces significant hurdles related to the safety risks inherent in prolonged usage. Extended exposure to corticosteroids can trigger severe adverse effects, including osteoporosis, hypertension, and hormonal imbalances, often resulting in patient non-compliance or prompting healthcare providers to switch to alternative treatments like biologics. This safety concern constitutes a major barrier to market expansion, as regulatory bodies and medical professionals remain cautious regarding the prescription of long-term corticosteroid regimens.

Market Driver

The escalating prevalence of chronic inflammatory and autoimmune disorders serves as a significant catalyst for the Global Corticosteroids Market. As conditions such as chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis become more widespread, the demand for effective anti-inflammatory and immunosuppressive interventions intensifies, creating a sustained patient base reliant on these drugs for symptom management and acute care. According to a November 2024 fact sheet by the World Health Organization, COPD accounted for 3.5 million deaths in 2021, demonstrating the vast scale of respiratory conditions requiring steroid intervention. Additionally, the American Lung Association's 'COPD Trends Brief' from March 2024 indicates that 11.7 million adults in the United States alone are affected, reinforcing the critical role these medications play in managing prevalent chronic illnesses.

Market expansion is further driven by the development of innovative formulations and combination therapies. Pharmaceutical companies are heavily investing in advanced drug delivery systems, such as fixed-dose combination inhalers that merge corticosteroids with long-acting beta-agonists and muscarinic antagonists, to enhance patient adherence and clinical efficacy. These technological improvements address compliance issues associated with complex dosing schedules, thereby boosting the commercial viability of steroid-based treatments. For instance, GSK's 'Annual Report 2023', released in February 2024, reported that global sales of Trelegy Ellipta, a single-inhaler triple therapy containing fluticasone furoate, reached £2.2 billion with 27% growth, illustrating how innovative delivery mechanisms secure market growth by offering superior convenience and outcomes compared to traditional monotherapies.

Market Challenge

Significant safety concerns regarding prolonged corticosteroid administration present a critical obstacle to the growth of the Global Corticosteroids Market. Although these drugs are clinically effective, their long-term use is inextricably linked to severe adverse events, such as metabolic and skeletal disorders. This risk profile compels healthcare providers to exercise considerable restraint when prescribing chronic regimens, effectively reducing the overall volume of corticosteroid utilization. The apprehension surrounding these side effects limits market potential, as clinicians increasingly prefer non-steroidal alternatives for long-term management.

This barrier is reinforced by recent clinical findings highlighting the magnitude of these risks in key patient populations. A 2024 study cited by the European Respiratory Society revealed that asthma patients on long-term corticosteroid therapy faced cumulative incidence rates of approximately 6.2% for type 2 diabetes and 2.6% for osteoporosis. Such data intensifies the urgency within the medical community to minimize steroid exposure, directly impacting market revenue as the industry witnesses a strategic pivot toward biologics and other steroid-sparing therapies that offer a more favorable safety profile.

Market Trends

The market is being reshaped by the advancement of extended-release injectable therapeutics, particularly for managing osteoarthritis pain where sustained, localized drug delivery is essential. Developers are leveraging proprietary microsphere technologies to formulate corticosteroids that provide prolonged analgesic effects while minimizing the systemic spikes typical of immediate-release injections. This innovation addresses the critical need for durable symptom relief in joint preservation, reducing the frequency of intra-articular administrations required for chronic conditions. Illustrating the commercial adoption of these long-acting formulations, Pacira BioSciences reported in February 2025 that net product sales of ZILRETTA, an extended-release triamcinolone acetonide injection, reached $118.1 million in 2024.

Simultaneously, there is a strategic shift toward localized and non-systemic administration routes, most notably within the ophthalmic sector, to overcome the compliance burdens associated with topical drops. Companies are introducing bioresorbable intracanalicular inserts and implants that deliver consistent steroid dosing directly to the target tissue, thereby ensuring treatment adherence and mitigating ocular surface toxicity. This approach effectively separates therapeutic efficacy from the patient's ability to self-administer complex regimens following eye surgeries. Underscoring this transition toward physician-administered systems, Ocular Therapeutix announced in March 2025 that total net revenue, driven principally by the sales of the dexamethasone ophthalmic insert DEXTENZA, rose to $63.7 million in 2024.

Key Market Players

• AbbVie Inc.
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.

Report Scope

In this report, the Global Corticosteroids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Corticosteroids Market, By Type

• Glucocorticoids
• Mineralocorticoids

Corticosteroids Market, By Route of Administration

• Inhaled
• Topical
• Injectable
• Oral

Corticosteroids Market, By Application

• Skin Allergies
• Gastroenterology
• Endocrinology
• Acute Respiratory Diseases
• Rheumatology Indications
• Others

Corticosteroids Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Corticosteroids Market.

Available Customizations:

Global Corticosteroids Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Corticosteroids Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Glucocorticoids, Mineralocorticoids)
  • 5.2.2. By Route of Administration (Inhaled, Topical, Injectable, Oral)
  • 5.2.3. By Application (Skin Allergies, Gastroenterology, Endocrinology, Acute Respiratory Diseases, Rheumatology Indications, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Corticosteroids Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Corticosteroids Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Corticosteroids Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Corticosteroids Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application

7. Europe Corticosteroids Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Corticosteroids Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
  • 7.3.2. France Corticosteroids Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Corticosteroids Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Corticosteroids Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Corticosteroids Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application

8. Asia Pacific Corticosteroids Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Corticosteroids Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
  • 8.3.2. India Corticosteroids Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Corticosteroids Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Corticosteroids Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Corticosteroids Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application

9. Middle East & Africa Corticosteroids Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Corticosteroids Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Corticosteroids Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Corticosteroids Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application

10. South America Corticosteroids Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Corticosteroids Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Corticosteroids Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Corticosteroids Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Corticosteroids Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca plc
• 15.3. Bayer AG
• 15.4. Eli Lilly and Company
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. GlaxoSmithKline plc
• 15.7. Merck & Co., Inc.
• 15.8. Novartis International AG
• 15.9. Pfizer Inc.
• 15.10. Sanofi S.A.

16. Strategic Recommendations

17. About Us & Disclaimer